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Summary: A method for synthesizing probes for detecting Hepatitis B virus DNA in serum was developed. It uses
DNA extracted from the serum of an Hepatitis B virus carrier äs target, and digoxigenin-11-dUTP incorporated in
| DNA sequences during the polymerase chain reaction äs tracer.
j
; Using a Spot hybridization assay, the sensitivity and specificity of the digoxigenin-labelled DNA probe were com-
; pared with two Standard Hepatitis B virus DNA probes, synthesized with cloned Hepatitis B virus DNA and labelled
either with digoxigenin or 32P by random priming. Data obtained from the three methods showed an excellent corre-
lation.
Thus, Hepatitis B virus DNA extracted from human serum and labelled by polymerase chain reaction may be
| considered a suitable alternative to cloned DNA. It provides reliable probes and eliminates the need for facilities
1 and personnel dedicated to the manipulation of clones. These advantages will allow a wider application of Hepatitis
j B virus DNA testing in clinical practice.
Introduction cation of the desired DNA fragment from an hetero-
_. _ , .. ^ . - „ . , geneous mixture of serum DNAs.The detection of hepatitis B virus DNA m serum by
spot-blot hybridization is an indication of viral repli- In this report we describe a method for synthesizing
cation and correlates with the patient's infectivity and specific DNA probes which use DNA extracted from
hepatic inflammatory activity (1-3). Although the the serum of an hepatitis B virus carrier äs target, and
widely-used detection of DNA by isotopic probes is digoxigenin-11-2^deoxyuridine-5'-triphosphate (digoxi-
highly sensitive, its use in clinical diagnosis is limited genin-11-dUTP) incorporated during polymerase chain
economically by the need for special facilities. For this reaetion, äs tracer. We compare the results obtained with
reason, non-isotopic probes have been proposed äs an this probe with those obtained with two hepatitis B virus
alternative (4). Recently, ä new non-radioactive System DNA probes (both from Eco RI fragment isolated from
was developed, which uses digoxigenin for labelling pCFSO plasmid containing four copies of cloned hepa-
DNA probes (5-6). Digoxigenin can be incorporated titis B virus DNA), labelled either with digoxigenin or
into a fragment of DNA by random priming or during 32P by random priming, in serum samples from patients
the polymerase chairi reaction (7). This last method has with chronic hepatitis B.
the advantage that DNA from serum may be used äs
target (8) instead of cloned DNA, because the specificity
of the polymerase chain reaction allows the amplifi- Materials and Methods
Patients
Two groups of subjects were studied:
') This work was supported in part by a grant from the Fondo de Group l included 150 patients with chronic B hepatitis, 60 HBeAg
Investigaciones de la Seguridad Social (FIS-92-1309) positive and 90 anti-HBe positive. The diagnosis of chronic hepa-
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titis was based on cvidcncc of persistent alteration in hepatic tests
for longer than six months, and the presence of chronic hepatitis
in an histological examination.
Group II consisted of 30 healthy blood donors without serological
markers of hepatitis B vims infection.
Serological assays
Sera were evaluated for HBsAg, anti-HBs, anti-HBc, HBeAg, and
anti-HBe by commercial radioimmunoassay kits: Ausria-II, Ausab,
Corab, Abbott HBe (Abbott Laboratories, North Chicago, IL).
Pu r i f i ca t i on and DNA label l ing by polymerase chain
reaction
Hepatitis B virus DNA was purified and extracted from serum
samples s previously described (9): digestion with proteinase K,
and extraction with phenol (once) and with chloroform/isoamyl-
alcohol (twice). Subsequently, the hepatitis B virus DNA was pre-
cipitated with ethanol in the presence of sodium acetate. For the
polymerase chain reaction assay, a set of sequences 20 nucleotides
long, specific for the hepatitis B virus pre-core/core region, was
synthesized and used s primers: Primer 1765, 5TCTTTGTAC-
TAGGAGGCTGT begins atposition 1765 of the hepatitis B virus
genome and primer 2458, 5'CTAACATTGAGATTCCCGAG (from
the complementary or reverse DNA Strand) begins at map position
2458 (10). The size of the amplified product is 694 base pairs. The
polymerase chain reaction was performed according to the protocol
ofSaiki et al. (11) with some modifications. Reactions were carried
out in a volume of 100 μΐ containing at least 10—20 pg of hepatitis
B virus DNA from serum, 200 μηιοΙ/1 of each deoxynucleotide
triphosphate (dATP, dCTP, dGTP) including dTTP (165 μπιοΐ/ΐ)
partially substituted with digoxigenin-11-dUTP (35 μηιοΐ/ΐ), 50
pmol of each primer and 2.5 U of Taq thermostable polymerase
(Boehringer Mannheim), in a buffer containing 50 mmol/1 KC1, 10
mmol/1 Tris-HCl (pH 8.3) and 1.5 mmol/1 MgCl2- The reaction was
performed for 35 cycles (1min 94 °C, 1min 60 °C and 3min
72 °C) in a programmable DNA Thermal Cycler (Perkin Eimer
Cetus). The specificity of the amplified product was confirmed by
Southern blot hybridization, using 32P labelled hepatitis B virus
DNA (isolated from pCF80) s probe. The sensitivity of the digoxi-
genin DNA probe was determined by testing decreasing dihitions
(500 to 0.5 pg) of plasmid DNA pCF80 in duplicate. As negative
control, plasmid pBR322 at a concentration of 200 pg was used.
To confirm the gene-specificity of the probe, another specific probe
from the Pre-S/S region was synthesized by a similar procedure,
and a crossed-hybridization experiment was designed in which
three parallel polymerase chain reaction techniques were used to
amplify three difFerent hepatitis B virus DNA fragments: one from
the Pre-core/core region (694 base pairs), another from the Pre-S/S
gene (567 base pairs) and a third which included a combiiiation of
both regions (1.9 X l O3 base pairs). After Southern blot transfer,
all three amplification products were hybridized separately with
each specific probe. Serum samples from healthy subjects who
tested negative for hepatitis B virus markers were used s controls.
DNA labell ing by random pr iming
Hepatitis B virus DNA (0.3 ug) from cloned hepatitis B virus DNA
pCFSO plasmid, kindly provided by Dr. C. Brechot, Paris, (contain-
ing four entire copies of hepatitis B virus genome inserted in the
Eco RI position) was labelled by random priming incorporation of
digoxigenin-11-dUTP (Boehringer Marinheim) or 32P (Amersham
Corporation) following the manufacturers instructions.
The rate of labelling was tested in the non-isotopic probes by seriaL
dilutions of each probe spotted on nylon membrane, followed by
colour reaction.
Hepatitis B virus DNA assay
The spot-blot hybridization technique described by Scotto et al. (3)
for the detection of hepatitis B virus DNA was used with minor
modifications (12). Seven microlitres of each sample were directly
denatured in 0.5 mol/1 NaOH, 1.5 mmol/I NaCl for 10 min, and
transferred by vacuum to a nylon membrane (Hybond-N. Amers-
ham). The nylon filters were always, prehybridized for at least 2 h
in 12.5 mol/1 formamide, saline/s dium citrate (0.75 raol/1 NaCl,
0.075 mol/1 Na-citrate), 0,02 mol/1 Na-phosphate (pH 6.5),
Denhardfs solution (0.1 g/l Ficoll (type 400, Pharmacia), 0.1 g/l
polyvinylpyrrolidone and 0.1 g/l bovine serum albumin (fraction
V, Sigma)) and 100 mg/1 salmon sperm DNA at 42 °C. Hybridiz-
ation was carried out in the same solution with either 100 μ^Ι of
non-radioactive probe or 10 μg/l of radioactive probe.
The positive hybridization with digoxigenin-labelled probes was
visualized by enzyme-linked immunoassay using an antibody-con-
jugate (antidigoxigenin alkaline phosphatase conjugate) and nitro-
blue tetrazolium/5-bΓomo-4-chloror3-indolyl·phosphate s colour
Substrates following the supplier's iristructipns (Boehringer
Mannheim) (6). Positive hybridizations with the radioactive probe
was detected by autoradiography (14h at — 70 °C) with Kodak
XAR-S film and Micron R intensifying screen.
The sensitivity of the two probes synthesized with cloned hepatitis
B virus DNA is 0.5 pg s previously described (12).
Results
DNA labelling by polymerase chain reaction
The polymerase chain reaction products were analysed
by agarose gel electrophoresis. The fragment obtained
without digoxigenin produced a clear band of 694 base
pairs corresponding to the expected length of the ampll··
fied region. The lower electrophoretic mobility of the
polymerase chain reaction products with digoxigenin
indicated that his hapten had been incorporated into the
DNA fragment with a resulting increase in molecular
mass (fig. 1). The differences in mobility between the
normal and the digoxigenin-labelled polymerase chain
reaction fragments permit an approximate estimate (de-
rived from a seinilog rithmic representation of mobility
vs. molecular mass, using the molecular m ss markers
for the Standard curve) of the number of hapten mol-
ecules incorporated (11-12 per probe molecule). This
estimate may be utilized s a first control to validate
the labelling process, in addition to the above described
dilution method. The dilution method detected up to
10~6 dilutions of the original polymerase chain reaction
probe solution.
Specificity and sensitivity of the serum
hepatitis B virus DNA probe synthesized by
polymerase chain reaction
The specificity of the polymerase chain reaction probes
was tested by dot and Southern blot hybridization, using
previously tested samples, which were positive for
HBeAg and hepatitis B virus»DNA, s positive controls.
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Ethidium bromide staining of amplified hepatitis B virus
Left: DNA markers, 123 ladder (Life Technologies. BRL).
Laues 1-3: Digoxigenin polymerase chain reaction probes using
difFerent amounts of target DNA (20,40 and 100 pg respectively).
Lanes 4 and 5: Polymerase chain reaction products from hepatitis
B virus DNA extracted from two different serum samples without
incorporation of digoxigenin in the polymerase chain reaction mix-
ture.
Patients from group II were used äs negative controls.
None of the negative controls produced positive Signals.
Some examples are shown in figure 2 (absence of hy-
bridization Signals in the negative lanes of Southern
blots) and in figure 3 (coordinates el, e2, e3 and e4 of
dot blots).
The specific probes labelled with digoxigenin for the
Pre-core/core and Pre-S/S regiöns hybridized exclus-
ively with the amplificatioia products of their respective
regiöns. lii neither case was cross-hybridization ob-
served. Moreover, both probes hybridized witb the large
amplified hepatitis B virus DNA fragment that included
the two regiöns. Neither of the two probes hybridized
with the negative controls (fig. 2).
Using spot test hybridization, the digoxigenin poly-
merase chain reaction-labelled probe detected äs little äs
0.5 pg of cloned hepatitis B virus, which is comparable
to the sensitivity obtained with random priming probes
(12).
Comparison of hybridization results
The results from the serum digoxigenin polymerase
chain reaction incorporated probe were compared with
results from the cloned hepatitis B virus DNA probes
labelled either with digoxigenin or 32P by random prim-
ing. Hepatitis B virus DNA was determined by Spot hy-
bridization in the serum of 150 HBsAg positive patients.
Hepatitis B virus DNA was detected in 68 (45%) of the
150 HBsAg positive serum specimen patients: fifty four
(90%) from HBeAg positive chronic hepatitis patients,
and fourteen (15%) from anti-HBe positive, with all
three methods. None of the 30 samples from the healthy
subjects was positive for hepatitis B virus DNA by any
of the three techniques. In some samples with positive
hybridization Signals the observed intensity was higher
in the non-radioactive methods than the radioactive one,
showing additionally a slightly different colour from that
expected. Sometimes it was necessary to overexpose a
filter in order to assure the presence of weak hybridiz-
ation Signals. As an example of the hybridization com-
parison, figure 3 shows a dot blot experiment including
a sample group of patients randomly selected from the
study population.
Discussion
The synthesis of DNA probes from human serum using
the polymerase chain reaction technique has not been
described previously. In this study, DNA extracted from
the serum of hepatitis B virus carriers was used äs the
target. By including a modified nucleotide with digoxi-
genin äs the tracer in the amplification mixture of a Stan-
dard polymerase chain reaction, specific non-radioactive
probes for determining hepatitis B virus DNA by spot-
hybridization were produced.
In the dot blot experiments (see fig. 3) the results ob-
tained with serum probes are the same äs those obtained
with the Standard probes with respect to the subsequent
clinical decision (i. e. positivity or negativity). In some
samples, however, differences in the intensity of the hy-
bridization Signals were observed between the radioac-
tive and the non-radioactive probes, the latter giving
more intense Signals than the former. These anomalous
Signals present a slightly different colour from those re-
maining, which may have been produced by some un-
known interference present in the original serum
samples. The results obtained in the Southern blot
experiment confirmed the expected specificity of the
serum polymerase chain reaction probes and disclosed a
characteristic property of polymerase chain reaction pro-
bes (from serum or cloned DNA) that can be called "se-
quence-specificity", based on the ability of the poly-
merase chain reaction process to produce concrete DNA
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Fig. 2 Specificity of the hepatitis B virus DNA polymerase chain
reaction serum probe.
AI Ethidium bromide staining of amplifled fragment from Pre
core/core.
A2 Hybridization of the Pre core/core polymerase chain reaction
products with the Pre core/core specific probe.
A3 Hybridization of the Pre core/core polymerase chain reaction
products with the Pre S/S probe.
B l Ethidium bromide staining of polymerase chain reaction pro-
ducts from Pre S/S.
B2 Hybridization of Pre S/S poiymefase chain reaction products
with a Pre core/core probe.
B3 Hybridization of Pre S/S polymerase chain reaction products
with a Pre S/S probe.
M: Molecular mass markers, 123 Ladder (BRL).
+ : Positive control.
—: Negative control.
Lanes 1—5: Random samples from the KBsAg positive patient
group.
C/S: Hybridization control: 1.9 X l O3 base pairs fragment includ-













Fig. 3 Comparison of the detection methods. Serum samples
from 28 patients were spotted on each of the three hybridization fil-
ters.
Filter A was hybridized with a 32P-labelled probe.
Filter B was hybridized with a digoxigenin-labelled probe synthe-.
sized by random priming using cloned hepatitis B virus DNA s
target.
Filter C was hybridized with a digoxigenin-labelled probe synthe^
sized <by polymerase chain reaction with hepatitis B virus DNA
extracted from human serum.
Non-radioactive hybridizations were detected by the colorimetric
method (see text).
Positive controls were spotted in positions e5, e6 and e7; and nega-
tive ones in positions el, e2, e3 and' e4.
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fragments defined by the selected set of primers. We
demonstrated this property in the experiment shown in
figure 2. A possible application of this property could
be the study of which genes are present in the partially
inserted hepatitis B virus DNA sequences observed
within the hepatocyte genome of asymptomatic hepatitis
B virus carriers or in hepatocellular carcinomas. Such a
study could be carried out using subcloned fragments of
hepatitis B virus DNA äs gene-specific probes, but the
protocol would be much more complex than in the me-
thod suggested above.
These results demonstrate that the sensitivity, specificity
and analytical applications of these probes are the same
äs those of conventional probes, prepared with cloned
DNA. Since they are synthesized with an amplification
process specific for a sequence of target DNA, the serum
probes may be used for detecting complete genomes, äs
well äs a particular sequence in heterogeneous DNA
mixtures.
The described method offers a number of methodolog-
ical advantages over the conventional techniques pre-
sently used. The characteristics of the polymerase chain
reaction reaction permit the use of DNA from hepatitis
B virus DNA present in the serum of an HBsAg-positive
patient, despite the complexity of this serum DNA,
which is a mixture of viral and human DNAs. Labelling
with digoxigenin permits the synthesis of large quantit-
ies of probe which may be stored at least one year with-
out losing activity. Moreover, this non-radioactive me-
thod avoids the inconveniences of radioactive isotopes
which have short half-lives and are difficult to handle in
a routine diagnosis laboratory.
Finally, the technology necessary for synthesizing this
type of probe is simple and may be easily implemented
in the clinical laboratory. The need for specialized equip-
ment, trained personnel and the extra time to carry out
molecular biology techniques such äs cloning, cellular
transformation or vector amplification, is completely
eliminated.
The resuits obtained from this study suggest that digoxi-
genin-labelled serum DNA probes may be a valid and
practical alternative to probes obtained from cloned
DNA.
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